Amgen Inc. $AMGN Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.5% in the 1st quarter, Holdings Channel reports. The firm owned 416,010 shares of the medical research company’s stock after selling 15,043 shares during the period. Janney Montgomery Scott LLC’s holdings in Amgen were worth $146,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC boosted its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the fourth quarter worth about $26,000. Tower View Wealth Management LLC increased its position in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC increased its position in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN opened at $358.61 on Friday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The stock’s 50 day moving average is $340.70 and its two-hundred day moving average is $346.20. The firm has a market capitalization of $193.54 billion, a PE ratio of 24.96, a P/E/G ratio of 3.60 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Canaccord Genuity Group started coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Morgan Stanley upped their price target on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 9th. Jefferies Financial Group initiated coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Finally, Royal Bank Of Canada reiterated a “positive” rating on shares of Amgen in a research report on Thursday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.